Cantex and Harvard's Wyss Institute to expand development of Azeliragon
Cantex also plans to initiate Phase 2 clinical trials exploring the therapeutic effect of azeliragon in pancreatic and breast cancers.
Cantex also plans to initiate Phase 2 clinical trials exploring the therapeutic effect of azeliragon in pancreatic and breast cancers.
Novel delivery of established growth and neurotrophic factors enables local, sustained release for greater efficacy
Subscribe To Our Newsletter & Stay Updated